Thomas Clozel, co-founder and CEO of OWKIN, elaborates on how AI can be applied to the pharmaceutical industry to revolutionize today’s drug discovery and development process. He also comments on the challenges facing the sector and how OWKIN is well positioned to overcome questions such as data privacy.
The big question in AI is how to get data and who the data belongs to
Speaking exclusively to PharmaBoardroom at the International Women’s Day 2020 event at the Franco-British Chamber of Commerce in Paris, esteemed cardiologist Professor Claire Mounier-Vehier outlines why cardiovascular disease is not…
Nathalie Giraud, director of integrated monitoring investigator services & head of France at PPD, breaks down the strengths and weaknesses of the French clinical trials environment and stresses the importance…
Francois Cornu, president of Eurofins Biomnis, and Gautier Decock, managing director of Eurofins BioPharma Product Testing in France and Belgium, come together to shed light on the company’s unique decentralized…
Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more. …
The latest news from French pharma, including AI-based biotech Owkin’s new status as a USD one billion-valued unicorn following fresh investment from Sanofi. Also included is another deal for Sanofi,…
The Top Five countries in Europe for pharma production. All located in Western Europe, Switzerland punches well above its weight to take top spot. This data is taken from the 2021…
See our Cookie Privacy Policy Here